Cargando…

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinelli, Brett, Kim, Edward, D'Alessio, Antonio, Cedillo, Mario, Sinha, Ishan, Debnath, Neha, Kudo, Masatoshi, Nishida, Naoshi, Saeed, Anwaar, Hildebrand, Hannah, Kaseb, Ahmed O, Abugabal, Yehia I, Pillai, Anjana, Huang, Yi-Hsiang, Khan, Uqba, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Patel, Rahul, Fischman, Aaron, Bishay, Vivian, Bettinger, Dominik, Sung, Max, Ang, Celina, Schwartz, Myron, Pinato, David J, Marron, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204420/ https://www.ncbi.nlm.nih.gov/pubmed/35710293 http://dx.doi.org/10.1136/jitc-2021-004205

Ejemplares similares

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
por: Fessas, Petros, et al.
Publicado: (2020)

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
por: Pinato, David J., et al.
Publicado: (2020)

Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
por: Pinato, David J, et al.
Publicado: (2020)

Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
por: Sharma, Rohini, et al.
Publicado: (2022)

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
por: Muhammed, Ambreen, et al.
Publicado: (2021)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
por: D’Alessio, Antonio, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
por: Jun, Tomi, et al.
Publicado: (2021)

Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
por: Naqash, Abdul Rafeh, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology
por: Choucair, Khalil, et al.
Publicado: (2022)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
por: Marie, Mona A., et al.
Publicado: (2022)

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
por: Joerg, Vincent, et al.
Publicado: (2023)

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
por: Fujiwara, Yu, et al.
Publicado: (2020)

The Mechanism of Enhanced Insulin Amyloid Fibril Formation by NaCl Is Better Explained by a Conformational Change Model
por: Muzaffar, Mahvish, et al.
Publicado: (2011)

Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
por: Yavuz, Betul Gok, et al.
Publicado: (2020)

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
por: Naqash, Abdul Rafeh, et al.
Publicado: (2023)

Water and sanitation risk exposure in children under-five in Pakistan
por: Murtaza, Fowad, et al.
Publicado: (2021)

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2018)

A Rare Case of Squamous Cell Carcinoma of the Esophagus in a Patient With Goltz Syndrome
por: Hafiz, Maida, et al.
Publicado: (2019)

Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy
por: Bishay, VL, et al.
Publicado: (2014)

Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications
por: Amara, Suneetha, et al.
Publicado: (2022)

Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma
por: Reincke, Marlene, et al.
Publicado: (2022)

Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using (18)F-Fluorothymidine PET
por: Sharma, Rohini, et al.
Publicado: (2020)

Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience
por: Bettinger, Dominik, et al.
Publicado: (2017)

Impact of Race on Outcomes of Advanced Stage Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
por: Pasli, Melisa, et al.
Publicado: (2023)

Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients
por: Teyateeti, Ajalaya, et al.
Publicado: (2020)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
por: D’Alessio, Antonio, et al.
Publicado: (2021)

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
por: Choucair, Khalil, et al.
Publicado: (2023)

Localized ablative immunotherapy drives de novo CD8(+) T-cell responses to poorly immunogenic tumors
por: Hoover, Ashley R, et al.
Publicado: (2022)

Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
por: Roehlen, Natascha, et al.
Publicado: (2023)

Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
por: Teyateeti, Ajalaya, et al.
Publicado: (2021)

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach
por: Han, Guohong, et al.
Publicado: (2020)

Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion
por: Waked, Imam, et al.
Publicado: (2017)

Advanced quantum image representation and compression using a DCT-EFRQI approach
por: Haque, Md Ershadul, et al.
Publicado: (2023)

Abstract No. 234 Interventional radiology case mix changes due to the COVID-19 pandemic
por: Carlon, T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5tf3vfbj55o8d34ge7kjdh4jie